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Background: Sirtuin1 (SIRT1) is an NAD+-dependent type III histone deacetylase (HDAC). This research investigated
the prevalence of SIRT1 protein expression and its prognostic influence with the aim of validating its potential role
in lymphangiogenesis and lymphovascular invasion (LVI) in pN0 esophageal squamous cell carcinoma (ESCC).
Methods: A total of 206 patients were enrolled in this retrospective study. SIRT1 and VEGF-C protein expression
was detected by immunohistochemical staining. Peritumoral lymphatic microvessel density (LVD) and LVI were
evaluated by immunostaining for D2-40. Statistical analysis was then preformed to investigate the relevance of
SIRT1 expression and various clinicopathologic features and to examine the effect of SIRT1 on tumor-induced
lymphangiogenesis, LVI and prognosis.
Results: SIRT1 positive expression was identified in 95 cases in the nucleus and was significantly correlated with T
status (P < 0.001), disease stage (P = 0.001), VEGF-C positive expression (P = 0.015), high LVD (P = 0.013) and positive
LVI (P = 0.015). Patients with SIRT1 positive expression, high LVD and positive LVI had a significantly unfavorable
5-year disease free survival (P < 0.001, P = 0.030, and P < 0.001, respectively) and overall survival (P < 0.001, P = 0.017,
and P < 0.001, respectively). However, based on multivariate Cox regression analysis, only SIRT1 positive expression
and positive LVI were significant independent prognosticators of poor disease-free survival (P = 0.029 and 0.018,
respectively) and overall survival (P = 0.045 and 0.031, respectively).
Conclusions: SIRT1 positive expression was significantly associated with tumor progression, lymphangiogenesis, LVI
and poor survival in pN0 ESCC patients. Our research shows a utilization of SIRT1 in prognosing poor survival and
providing possible target for ESCC patients through inhibiting its lymphangiogenesis activity.
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Esophageal cancer (EC) is one of the most common ma-
lignancies worldwide, and it ranks as the sixth major
cause of cancer-related death [1]. Esophageal squamous
cell carcinoma (ESCC) is the predominant subtype of this
lethal disease, especially in China. Annually, appro-
ximately half of the newly diagnosed EC patients world-
wide are Chinese, and nearly 90% of these patients have
ESCC [2-4]. In the past few decades, with the progress in* Correspondence: tianhuiql@126.com
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juvant therapy, the outcome of EC has been improved;
however, the 5-year survival rate remains low, especially in
patients with lymph node metastasis [5,6]. However, even
in patients without lymph node metastasis (pN0), some of
them still develop metastasis and have poor prognosis
after surgery [7]. Until now, efficient biomarkers for pN0
ESCC patients that could be useful for further risk classi-
fication have not been identified. Thus, identification of
prognostic molecular markers for pN0 ESCC may help to
identify patients with poor prognosis who would benefittd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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peutic targets and improve the long-term survival rate.
Protein acetylation plays an important role in cancer
development and progression [8]. Sirtuin1 (SIRT1) is an
NAD+-dependent type III histone deacetylase (HDAC)
[9]. By diminishing the acetylation of histones and non-
histone substrates, such as p53 and p73, SIRT1 partici-
pates in various signaling pathways related to aging,
DNA repair, metabolic regulation, apoptosis, and pro-
liferation [10-12]. Although much research has been
performed on SIRT1, its role in tumorigenesis in spe-
cific cancers, even in the same cancer type, is still con-
troversial [13]. It has been shown that SIRT1 positive
expression is strongly associated with tumorigenesis
and tumor progression in various cancer types, such as
colorectal cancer [14], gastric carcinoma [15], prostate
cancer [16], lung cancer [17], and breast cancer [18].
However, convincing evidence has also demonstrated
the tumor suppressor function of SIRT1 [19,20]. Until
now, no studies have evaluated the correlation of
SIRT1 with clinicopathologic characteristics and prog-
nosis in ESCC.
Lymph metastasis is the dominant means by which
ESCC disseminates systemically [21,22], and it has been
shown to be correlated with enhanced lymphangiogen-
esis and positive LVI in some cancer types [23,24].
Nonetheless, data on lymphangiogenesis and LVI in
ESCC are still rare. A recent report has indicated that
VEGF-C, the primary mediator of lymphangiogenesis, is
a downstream factor regulated by SIRT1 [25]. To the
best of our knowledge, this is the first clinical study to
examine the expression level of SIRT1 protein in pN0
ESCC patients and to elucidate the relationship between
SIRT1 protein expression and various clinicopathologic
features, tumor lymphangiogenesis, LVI and prognosis.
Results
Correlations among SIRT1, VEGF-C and
clinicopathologic features
SIRT1 positive expression was detected mainly in the
nuclei, while VEGF-C was found in the cytoplasm
(Figure 1A). Among the 206 patients, 95 (46.1%) showed
SIRT1 positive expression, while 111 (53.9%) showed
SIRT1 negative expression (Figure 1A). A total of 107
(51.9%) patients showed VEGF-C positive expression,
while 99 (48.1%) showed VEGF-C negative expression
(Figure 1A). Moreover, negative controls (PBS) showed no
immunostaining. Correlations among SIRT1, VEGF-C and
clinicopathologic characteristics are shown in Table 1.
To further analyze the expression level of SIRT1 in
ESCC, we performed western blot analysis in 11 fresh
biopsies of paired primary tumor tissue and correspon-
ding nontumorous tissue. As shown in Figure 1B, the re-
sults confirmed the overexpression of SIRT1 in ESCCtumor tissues when compared with paired nontumorous
tissues.
SIRT1 positive expression was significantly correlated
with T status (P < 0.001) and stage (P = 0.001). No other
significant associations were observed between SIRT1
expression and age, gender, differentiation, weight loss,
tumor location, or length of tumor (P > 0.05).
VEGF-C positive expression was significantly correlated
with T status (P = 0.025) and stage (P = 0.001). However,
no other clinicopathologic features were significantly asso-
ciated with VEGF-C positive expression (P > 0.05).
Correlations among lymphatic microvessel density (LVD),
LVI and clinicopathologic features
Lymphatic vessels were detected by staining of D2-40,
which is specifically expressed in the lymphatic endothe-
lium but not in vascular endothelial cells (Figure 1A). Of
the 206 tissues, 83 (40.3%) showed high LVD, and 71
(34.5%) showed positive LVI. There was no significant
relationship between LVD and any clinicopathologic fea-
tures (P > 0.05, Table 1). However, positive LVI was sig-
nificantly correlated with differentiation (P = 0.027), T
status (P = 0.036) and stage (P = 0.039). No other clinico-
pathologic features showed a significant association with
positive LVI (P > 0.05).
Correlations among SIRT1, VEGF-C, LVD and LVI
As shown in Table 2, SIRT1 positive expression was sig-
nificantly correlated with VEGF-C positive expression
(P = 0.015). Additionally, the LVD was greater in SIRT1-
positive tissues and VEGF-C-positive tissues (P = 0.013
and 0.005, respectively). Positive LVI was also increased in
SIRT1-positive tissues (P = 0.015), VEGF-C-positive tis-
sues (P = 0.007) and tissues with high LVD (P = 0.027).
Correlations among SIRT1, VEGF-C, LVD, LVI and tumor
recurrence
Recurrence occurred in 75 (36.4%) patients during 5-
year follow-up. A total of 19 patients were diagnosed
with locoregional relapse, 34 patients were diagnosed
with distant metastasis, and 22 patients were diagnosed
with both locoregional relapse and distant metastasis.
Overall, 51 (53.7%) of the 95 SIRT1-positive patients and
24 (21.6%) of the 111 SIRT1-negative patients suffered
tumor relapse (P < 0.001, chi-square test). Tumor recur-
rence was observed in 44 (41.1%) of 107 VEGF-C-
positive patients and 31 (31.3%) of 99 VEGF-C-negative
patients (P = 0.144, chi-square test). In 83 cases with
high LVD, 38 (45.8%) patients developed tumor relapse,
and in 123 cases with low LVD, 37 (30.1%) patients de-
veloped tumor relapse (P = 0.022, chi-square test). A
total of 40 (56.3%) of 71 patients with positive LVI and
35 (25.9%) of 135 patients with negative LVI suffered
tumor relapse (P < 0.001, chi-square test). Kaplan-Meier
Figure 1 SIRT1, VEGF-C and D2-40 expression in esophageal tissue samples. (A) Immunohistochemical staining of SIRT1, VEGF-C protein,
lymphatic microvessels and lymphovascular invasion in pN0 ESCC tissues: (a) SIRT1 positive expression; (b) SIRT1 negative expression (magnification ×
400); (c) VEGF-C protein positive expression; (d) VEGF-C protein negative expression (magnification × 400); (e) lymphatic microvessel labeled with D2-
40 in peritumoral stromal tissue (magnification × 200); (f) lymphovascular invasion highlighted by D2-40 (magnification × 400). (B) SIRT1 protein
expression was evaluated by western blotting in ESCC tissues and paired noncancerous tissues.
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that SIRT1 positive expression (P < 0.001, Figure 2a),
high LVD (P = 0.030, Figure 2b) and positive LVI (P <
0.001, Figure 2c) had significantly unfavorable prognostic
influences. To objectively reflect the prognostic influ-
ence of the risk factors that were detected in univariate
analysis, only significant risk factors were further tested
by multivariate Cox regression analysis. However, based
on multivariate analysis, only SIRT1 positive expression
(P = 0.029) and positive LVI (P = 0.018) were independ-
ent prognostic factors for DFS (Table 3).
Univariate and multivariate survival analyses
The overall 5-year survival rate was 64.6%, and 73 pa-
tients eventually died after the operation. We found that
patients with SIRT1 positive expression had a signifi-
cantly shorter 5-year overall survival (OS) than patients
who lacked SIRT1 expression (48.4% vs 78.4%; P < 0.001,
Figure 2d). High LVD was also significantly associated
with worse 5-year OS compared with low LVD (54.2% vs
71.5%, P = 0.017, Figure 2e). In addition, positive LVI
was also associated with a significantly shorter 5-year OS
than negative LVI (46.5% vs 74.1%, P < 0.001, Figure 2f).
There was no significant association between VEGF-C
positive expression and poor 5-year OS (P = 0.258,Table 3). Furthermore, multivariate Cox regression
analysis revealed that SIRT1 positive expression (P =
0.045) and positive LVI (P = 0.031) were independent
prognosticators of poor OS (Table 3).
Discussion
SIRT1 protein, which plays an important role in deacety-
lation, has been demonstrated to be involved in tumori-
genesis and lymph node metastasis in various types of
human cancers [14-17]. To the best of our knowledge, this
is the first report examining the expression of SIRT1 pro-
tein in pN0 ESCC patients and the first demonstration of
the relationship between SIRT1 protein and clinicopatho-
logic features, lymphangiogenesis, LVI and prognosis. Our
results indicate that SIRT1 protein may have a tumor-
promoting function in ESCC patients, as its positive
expression was significantly correlated with T status
and stage.
Recent reports have indicated that deacetylation of
FOXO-1 by SIRT1 could enhance VEGF-C transcription
in the nuclei of prostate cancer cells and facilitate the
growth of endothelial cells in mice [13,25]. Thus, we
hypothesized that SIRT1 may also enhance VEGF-C
transcription in ESCC. According to our findings,
SIRT1 positive expression in the nucleus was significantly
Table 1 Correlation of clinicopathologic characteristics with SIRT1 protein, VEGF-C protein, LVD and LVI

















Gender 0.975 0.516 0.171 0.897
Male 82 70 71 81 95 57 100 52
Female 29 25 28 26 28 26 35 19
Age (year) 0.697 0.786 0.842 0.327
<50 30 28 27 31 34 24 35 23
≥50 81 67 72 76 89 59 100 48
Weight loss (kg) 0.205 0.834 0.940 0.239
<2.5 67 49 55 61 69 47 80 36
≥2.5 44 46 44 46 54 36 55 35
Length of tumor (cm) 0.654 0.492 0.991 0.980
<3 45 43 45 43 53 35 58 30
3-5 55 41 42 54 57 39 63 33
>5 11 11 12 10 13 9 14 8
Differentiation 0.070 0.125 0.294 0.027
Well 27 13 25 15 28 12 30 10
Moderate 56 62 53 65 69 49 81 37
Poor 28 20 21 27 26 22 24 24
Tumor location 0.227 0.083 0.765 0.370
Upper 17 8 17 8 16 9 19 6
Middle 56 57 49 64 65 48 70 43
Lower 38 30 33 35 42 26 46 22
T status <0.001 0.025 0.439 0.036
T1 26 7 23 10 23 10 26 7
T2 63 47 48 62 64 46 75 35
T3 22 41 28 35 36 27 34 29
Stage 0.001 0.001 0.069 0.039
I 30 13 31 12 32 11 35 8
IIa 47 28 35 40 44 31 48 27
IIb 34 54 33 55 47 41 52 36
LVD: lymphatic microvessel density.
LVI: lymphovascular invasion.
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possible role for SIRT1 in regulating VEGF-C expression
in ESCC; however, these findings are preliminary. The
specific molecular mechanism underlying this process
is still not well understood and requires further eluci-
dation in the future. It has been shown that VEGF-C is
an essential factor in lymphangiogenesis [26] and LVD
can significantly affect LVI [24]; thus, we also tested
the correlation among VEGF-C, LVI and LVD and the
possible relevance of SIRT1, LVI and LVD. As shown
in Table 2, VEGF-C and LVI were significantly corre-
lated with LVD, in accordance with previous reports
[27,28]. Additionally, our results showed a significantlyhigh LVD and positive LVI in patients with SIRT1 posi-
tive expression, indicating an important role for SIRT1
in promoting tumor lymphangiogenesis and lymphatic
metastasis.
Until now, studies on lymphangiogenesis and LVI in
ESCC patients have been rare and contradictory, and
there are no available data for pN0 ESCC patients. Previ-
ous studies have shown that ESCC patients with high
LVD have a significantly worse prognosis [29], while
Schoppmann [28] showed a significant prognostic impact
in adenocarcinomas only. On the other hand, positive LVI
has been shown to be a significant prognosticator for all
types of esophageal cancers.
Table 2 Correlations between SIRT1, VEGF-C, LVD and LVI


















Negative 62 37 - -
Positive 49 58 - -
LVD 0.013 0.005 -
Low 75 48 69 54 - -
High 36 47 30 53 - -
LVI 0.015 0.007 0.027
Negative 81 54 74 61 88 47 - - -
Positive 30 41 25 46 35 36 - -
LVD: lymphatic microvessel density.
LVI: lymphovascular invasion.
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currence and worse OS in patients with high LVD, posi-
tive LVI and SIRT1 positive expression. However,
although VEGF-C positive expression was significantly
correlated with T status and stage, which agreed with
previous research [30], VEGF-C positive expression was
not prognostic for poor DFS or OS. These results may
be due to the complexity of lymphangiogenesis regula-
tion, the heterogeneity of the microenvironment of dif-
ferent cancer types and the activation of different
signaling pathways, even in the same tumor type, at dif-
ferent stages. Univariate analysis revealed the value of
LVD, LVI and SIRT1 in prognosing tumor relapse and
poor OS. However, based on multivariate analysis, only
SIRT1 positive expression and positive LVI remained as
independent prognostic factors for both DFS and OS.
Taken together, these results support the hypothesis that
SIRT1 may promote tumor progression partially by in-
duction of lymphangiogenesis and LVI.
It should be noted that the mechanisms of tumor lym-
phangiogenesis and lymphatic metastasis are exception-
ally complex, and the exact role of SIRT1 protein in
lymphangiogenesis and lymphatic metastasis remains to
be further studied. Recent reports have indicated that
tumor-induced lymphangiogenesis may not only supply
a number of draining tubes for cancer cell metastasis
but may also regulate host immune status and reflect
changes in the tissue microenvironment [31]. Debates
regarding the function of peritumoral and intratumoral
lymphatic vessels are ongoing. In esophageal cancer, this
contradiction is mainly due to the different definition of
intratumoral lymphatic vessels. Lymphatic vessels are al-
ways found in peritumoral stromal tissue [28].
The debate regarding the function of SIRT1 in tumori-
genesis is ongoing. Because SIRT1 participates in various
signaling pathways [10-12], it may function differently in
each case. Tumorigenesis is an extremely complexprocess involving numerous signaling pathways; thus,
the importance of SIRT1 in specific tumors may also
vary. Further studies will be undertaken in the future,
and autologous normal tissues may also be used to help
us further understand the role of SIRT1 in tumorigenesis
in ESCC patients.
Conclusion
In conclusion, our study revealed the potential role of
SIRT1 protein in the progression, lymphangiogenesis
and lymphatic metastasis of pN0 ESCC. In addition, we
showed that positive expression of SIRT1 protein was
significantly associated with unfavorable prognosis, indi-
cating that SIRT1 protein may be useful in predicting




Between January 2004 and December 2007, 206 patients
who were diagnosed with pN0 ESCC by pathological
examination after operation at the Department of Thor-
acic Surgery, Qilu Hospital, were enrolled in this retro-
spective study. For western blotting analysis, 11 matched
pairs of freshly biopsied tumor tissues and correspond-
ing nontumorous tissues were collected immediately
after resection between October 2013 and November
2013 in our department and stored at −80°C. All pa-
tients underwent esophagectomy and esophagogastric
anastomosis with regional lymph node dissection. Of all
the 206 patients, 2556 lymph nodes were dissected
(mean of 12.4 per case, ranging from 10 to 19). Informa-
tion on the patients’ follow-up and clinicopathologic
features were collected. None of patients received
chemotherapy or radiotherapy before surgery. This re-
search was approved by the Ethics Committee of Qilu
Hospital.
Figure 2 Kaplan-Meier survival analysis of ESCC patients. Disease-free survival stratified by SIRT1 expression (a), LVD (b), LVI (c). Overall
survival stratified by SIRT1 expression (d), LVD (e), LVI (f).
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Table 3 Univariate and multivariate analyses of prognostic variables
Variables Univariate analysis Multivariate analysis
Pa Pb HR (95.0% CI)a Pa HR (95.0% CI)b Pb
Age 0.928 0.832
Gender 0.192 0.243
Weight loss 0.573 0.578
Length of tumor 0.685 0.623
Tumor location 0.358 0.292
Differentiation 0.017 0.023 1.302 (0.861-1.971) 0.211 1.271 (0.835-1.934) 0.262
T status <0.001 <0.001 1.828 (1.176-2.842) 0.007 1.742 (1.116-2.720) 0.015
Stage <0.001 <0.001 1.567 (1.032-2.381) 0.035 1.538 (1.010-2.342) 0.045
VEGF-C 0.172 0.258
LVI <0.001 <0.001 1.782 (1.106-2.872) 0.018 1.702 (1.050-2.757) 0.031
LVD 0.030 0.017 1.146 (0.720-1.823) 0.565 1.244 (0.777-1.991) 0.364
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from 40 to 78 years (mean 58.57 ± 11.65 years). Accord-
ing to the TNM classification system of the 7th edition
of the AJCC Cancer Staging criteria, tumor stage was
ascertained after surgery by expert pathologists. The
clinicopathological characteristics of the patients are
shown in Table 4.
Follow-up
Follow-up began on the day of hospital discharge. Pa-
tients were instructed to report to the outpatient clinic
for follow-up evaluation once every 3 to 6 months and
annually after the fifth year. Each evaluation included a
physical and blood examination. Barium esophagram
and chest radiography were performed every 3 months,
and CT of the thorax and ultrasound were performed
every 6 months in the first five years and once a year from
then on. Fiberesophagoscopy and other specific proce-
dures, such as MRI and emission computed tomography
(ECT), were also preformed if necessary. Relapse was de-
termined by pathological or radiological examination.
Follow-up ended in March 2013, and it ranged from 5 to
86 months for all patients (average 55.9 months).
Immunohistochemical staining
Immunohistochemistry was used to evaluate the expres-
sion of SIRT1, D2-40 and VEGF-C. Formalin-fixed and
paraffin-embedded 4-μm thick tumor tissue slices were
dewaxed and rehydrated before antigen retrieval. The
microwave antigen retrieval method was then utilized,
and the slides were immersed in EDTA antigen retrieval
solution (pH 9.0) for 15 min. Subsequently, we added
3% hydrogen peroxide to the slides to inhibit endogenousperoxidase activity. Subsequently, SIRT1 (1:150; Abcam,
Cambridge, UK), D2-40 (FLEX Ready-to-Use; Dako,
Glostrup Denmark), and VEGF-C (1:100; Zhongshan
Biotech, Beijing China) were applied to the sections that
were later incubated at 4°C overnight (the incubation
time of D2-40 was 25 minutes at room temperature ac-
cording to the manufacturer’s recommendation). On the
second day, biotinylated antibody and streptavidin-
peroxidase reagent (Zhongshan Biotech, Beijing China)
were successively applied for 15 min each at 37°C. Finally,
3,3’-diaminobenzidine tetrahydrochloride (DAB) was used
for visualization, and hematoxylin was added as a
counterstain.
The positive controls were human non-small cell lung
cancer tissues expressing SIRT1 and VEGF-C protein.
Sections that were incubated with PBS instead of pri-
mary antibodies were used as negative controls. Both the
positive and negative controls were used to evaluate the
reliability of staining and exclude nonspecific reactions.
Western blotting analysis
Total proteins extracted from fresh tissues were pre-
pared in radio immunoprecipitation assay (RIPA) buffer
(Beyotime, Jiangsu, China) including complete protease
inhibitor cocktail (Roche Applied Science, Mannheim,
Germany). Total proteins were separated by 10% SDS-
PAGE and then transferred to PVDF membranes. The
membranes were blocked with 5% skim milk in Tris-
buffered saline with 0.1% Tween-20 (TBST) for 1 h at
room temperature and then incubated with anti-SIRT1
(1:1000; Abcam, Cambridge, UK) or anti-GAPDH
(1:1000; Abcam, Cambridge, UK) antibodies overnight
at 4°C. After incubation with horseradish peroxidase-
Table 4 Clinicopathological characteristics of the patients
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proteins were detected using enhanced chemilumines-
cence (Millipore, Billerica, MA).
Evaluation
The expression levels of SIRT1 and VEGF-C protein
were calculated utilizing a semiquantitative scoring sys-
tem. The staining score was classified as 0 (negative
staining), 1 (weak staining), 2 (moderate staining) and 3
(strong staining). The quantity score, which represented
the percentage of cancer cells that were positively
stained, was calculated as follows: 0 (0-5%), 1 (6-25%), 2
(26-50%), 3 (51-75%), and 4 (≥76%). By multiplying the
staining score by the quantity score of each slide, the
final semiquantitative score was obtained (ranging from
0 to 12). Scores that ranged from 4–12 were considered
to represent positive expression [16,32].
Lymphatic microvessel density (LVD) was measured
by quantifying vessels stained with D2-40. Three hot
spots (the largest vessel density area stained) were first
recognized at low power (×100), and then vessels were
counted at high magnification (×200). The average num-
ber of positive vessels in six high-power areas (counted
by two investigators) for each slide represents the LVD
value. Tumors were categorized as High LVD and Low
LVD according to the average LVD (16.07 ± 5.748 micro-
vessels per × 200 magnification field (range from 0–29)).
An LVD < 17 or ≥ 17 was designated as Low LVD or
High LVD, respectively [33]. D2-40-stained lymphatic
vessels containing at least one tumor cell were defined
as Positive LVI [34].
Statistical analysis
The SPSS software package (18.0; SPSS, Chicago, IL,
USA) was used for statistical analysis. Correlations
among SIRT1, VEGF-C, LVD, LVI and various clinico-
pathologic characteristics were compared using the chi-
square test. Survival curves were constructed using the
Kaplan-Meier method, and the significance of differ-
ences in the survival of subgroups was examined with
the log rank test. Independent prognostic factors were
determined by multivariate Cox regression analysis. P
values less than 0.05 were considered significant.
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